<DOC>
	<DOCNO>NCT02385617</DOCNO>
	<brief_summary>Improvements treatment strategy patient upper gastrointestinal cancer produce increase population people remain free disease recurrence long term . Weight loss nutritional problem common among patient attain long-term remission cure surgery upper gastrointestinal cancer . However , mechanism underlie problem well understood . In study investigator aim determine whether reduce food intake upper gastrointestinal surgery cause early satiety relate exaggerated post-prandial gut hormone responses . This randomized , double-blind , placebo control , crossover study effect 100Î¼g octreotide SC ad libitum food intake patient free complication recurrence least one year post-oesophagectomy , gastrectomy pancreaticoduodenectomy . A comparator group age , weight gender match subject study concurrently , caloric intake subjective symptom score administration octreotide versus placebo among surgical comparator subject assess .</brief_summary>
	<brief_title>Food Intake Gut Hormones Patients Who Have Undergone Upper Gastrointestinal Surgery Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Malnutrition</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Surgical procedure : Twostage , threestage transhiatal oesophagectomy gastric conduit reconstruction pyloroplasty , total gastrectomy RouxenY reconstruction , pancreaticodueodenectomy , match unoperated healthy control 2 . At least one year remission postresection ( surgical group ) 1 . Pregnancy , breastfeed 2 . Significant persistent chemoradiotherapy and/or surgical complication 3 . Other previous upper gastrointestinal surgery 4 . Significant dysphagia odynophagia , unable eat 5 . Other disease medication may affect satiety gut hormone responses 6 . Active significant psychiatric illness include substance misuse 7 . Cognitive communication issue factor affect capacity consent participation 8 . History significant food allergy , certain dietary restriction 9 . Confirmed suspected residual recurrent disease surgery , second primary malignancy 10 . Other reconstruction ( eg colonic jejunal interposition ) 11 . Any contraindication octreotide administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Glucagon-Like Peptide 1</keyword>
	<keyword>Peptide YY</keyword>
	<keyword>Ghrelin</keyword>
	<keyword>Satiety Response</keyword>
	<keyword>Appetite</keyword>
	<keyword>Hunger</keyword>
	<keyword>Somatostatin</keyword>
	<keyword>Octreotide</keyword>
	<keyword>Anastomosis , Roux-en-Y</keyword>
	<keyword>Digestive System Surgical Procedures</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Enteroendocrine Cells</keyword>
	<keyword>Gastrointestinal Agents</keyword>
</DOC>